to the Secretary of Health and Human Services. In 
issuing an order under paragraph (1), the Attorney 
General shall take into consideration any comments 
submitted by the Secretary in response to a notice 
transmitted pursuant to this paragraph. 
‘‘(4) A temporary scheduling order issued under 
paragraph (1) shall be vacated upon the issuance of 
a permanent scheduling order under paragraph (6). 
‘‘(5) An order issued under paragraph (1) is not 
subject to judicial review. 
‘‘(6) The Attorney General may, by rule, issue a 
permanent order adding a drug or other substance to 
the definition of anabolic steroids if such drug or 
other substance satisfies the criteria for being consid-
ered an anabolic steroid under section 102(41). Such 
rulemaking may be commenced simultaneously with 
the issuance of the temporary order issued under 
paragraph (1).’’. 
(c) LABELING REQUIREMENTS.— 
(1) IN GENERAL.—The Controlled Substances Act 
is amended by inserting after section 305 (21 U.S.C. 
825) the following: 
‘‘SEC. 305A. OFFENSES INVOLVING FALSE LABELING OF AN-
ABOLIC STEROIDS. 
‘‘(a) UNLAWFUL ACTS.— 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6203
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
‘‘(1) It shall be unlawful— 
‘‘(A) to import into the United States or to 
export from the United States; 
‘‘(B) to manufacture, distribute, dispense, 
sell, or offer to sell; or 
‘‘(C) to possess with intent to manufacture, 
distribute, dispense, sell, or offer to sell; 
any anabolic steroid, or any product containing an 
anabolic steroid, that does not bear a label clearly 
identifying any anabolic steroid contained in such 
steroid or product by the nomenclature used by the 
International Union of Pure and Applied Chemistry 
(IUPAC). 
‘‘(2)(A) A product described in subparagraph 
(B) is exempt from the International Union of Pure 
and Applied Chemistry nomenclature requirement of 
this subsection if such product is labeled in the man-
ner required under the Federal Food, Drug, and Cos-
metic Act. 
‘‘(B) A product is described in this subpara-
graph if the product— 
‘‘(i) is the subject of an approved applica-
tion as described in section 505(b) or (j) of the 
Federal Food, Drug, and Cosmetic Act; or 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6203
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
‘‘(ii) is exempt from the provisions of sec-
tion 505 of such Act relating to new drugs be-
cause— 
‘‘(I) it is intended solely for investiga-
tional use as described in section 505(i) of 
such Act; and 
‘‘(II) such product is being used exclu-
sively for purposes of a clinical trial that is 
the subject of an effective investigational 
new drug application. 
‘‘(b) CRIMINAL PENALTIES.—Any person who violates 
subsection (a) knowing, intending, or having reasonable 
cause to believe, that the substance or product is an anabolic 
steroid, or contains an anabolic steroid, shall be sentenced 
to a term of imprisonment of not more than 10 years, a 
fine not to exceed the greater of that authorized in accord-
ance with the provisions of title 18, United States Code, 
or $500,000 if the defendant is an individual or $2,500,000 
if the defendant is other than an individual, or both. 
‘‘(c) CIVIL PENALTIES.— 
‘‘(1) Any person who violates subsection (a) shall 
be subject to a civil penalty as follows: 
‘‘(A) In the case of an importer, exporter, 
manufacturer, or distributor (other than as pro-
vided in subparagraph (B)), up to $500,000 per 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6203
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
violation. For purposes of this subparagraph, a 
violation is defined as each instance of importa-
tion, exportation, manufacturing, or distribu-
tion, and each anabolic steroid or product im-
ported, exported, manufactured, or distributed. 
‘‘(B) In the case of a sale or offer to sell at 
retail, up to $25,000 per violation. For purposes 
of this subparagraph, each sale and each product 
offered for sale shall be considered a separate vio-
lation. Continued offers to sell by a person 10 or 
more days after written notice (including 
through electronic message) to the person by the 
Attorney General or the Secretary shall be con-
sidered additional violations. 
‘‘(2) In this subsection, the term ‘product’ means 
a discrete article, either in bulk or in finished form 
prepared for sale. A number of articles, if similarly 
packaged and bearing identical labels, shall be consid-
ered as one product, but each package size, form, or 
differently labeled article shall be considered a sepa-
rate product. 
‘‘(d) IDENTIFICATION AND PUBLICATION OF LIST OF 
PRODUCTS CONTAINING ANABOLIC STEROIDS.— 
‘‘(1) The Attorney General may, in his discre-
tion, collect data and analyze products to determine 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6203
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
whether they contain anabolic steroids and are prop-
erly labeled in accordance with this section. The At-
torney General may publish in the Federal Register 
or on the website of the Drug Enforcement Adminis-
tration a list of products that he has determined, 
based on substantial evidence, contain an anabolic 
steroid and are not labeled in accordance with this 
section. 
‘‘(2) The absence of a product from the list re-
ferred to in paragraph (1) shall not constitute evi-
dence that the product does not contain an anabolic 
steroid.’’. 
(2) TABLE OF CONTENTS.—The table of contents 
for the Comprehensive Drug Abuse Prevention and 
Control Act of 1970 is amended by inserting after the 
item relating to section 305 the following: 
‘‘Sec. 305A. Offenses involving false labeling of anabolic steroids.’’. 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Designer An-
abolic Steroid Control Act of 2014’’. 
SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES 
ACT. 
(a) DEFINITIONS.—Section 102(41) of the 
Controlled Substances Act (21 U.S.C. 802(41)) 
is amended— 
(1) in subparagraph (A)— 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6202
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
(A) in clause (xlix), by striking 
‘‘and’’ at the end; 
(B) by redesignating clause (xlx) 
as clause (lxxv); and 
(C) by inserting after clause (xlix) 
the following: 
‘‘(l) 5α-Androstan-3,6,17-trione; 
‘‘(li) 6-bromo-androstan-3,17-dione; 
‘‘(lii) 6-bromo-androsta-1,4-diene-3,17- 
dione; 
‘‘(liii) 
4-chloro-17α-methyl-androsta- 
1,4-diene-3,17β-diol; 
‘‘(liv) 
4-chloro-17α-methyl-androst-4- 
ene-3β,17β-diol; 
‘‘(lv) 4-chloro-17α-methyl-17β-hydroxy- 
androst-4-en-3-one; 
‘‘(lvi) 
4-chloro-17α-methyl-17β-hy-
droxy-androst-4-ene-3,11-dione; 
‘‘(lvii) 
4-chloro-17α-methyl-androsta- 
1,4-diene-3,17β-diol; 
‘‘(lviii) 
2α,17α-dimethyl-17β-hydroxy- 
5α-androstan-3-one; 
‘‘(lix) 2α,17α-dimethyl-17β-hydroxy-5β- 
androstan-3-one; 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6202
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
‘‘(lxxiii) 
[3,2-c]pyrazole-androst-4-en- 
17β-ol; 
‘‘(lxxiv) 
[3,2-c]pyrazole-5α-androstan- 
17β-ol; and’’; and 
(2) by adding at the end the fol-
lowing: 
‘‘(C)(i) Subject to clause (ii), a drug or hor-
monal 
substance 
(other 
than 
estrogens, 
progestins, 
corticosteroids, 
and 
dehydroepiandrosterone) that is not listed in 
subparagraph (A) and is derived from, or has 
a chemical structure substantially similar to, 
1 or more anabolic steroids listed in subpara-
graph (A) shall be considered to be an ana-
bolic steroid for purposes of this Act if— 
‘‘(I) the drug or substance has 
been created or manufactured with 
the intent of producing a drug or 
other substance that either— 
‘‘(aa) promotes muscle growth; 
or 
‘‘(bb) otherwise causes a phar-
macological effect similar to that 
of testosterone; or 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6202
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
‘‘(II) the drug or substance has 
been, or is intended to be, marketed 
or otherwise promoted in any manner 
suggesting that consuming it will pro-
mote muscle growth or any other 
pharmacological effect similar to that 
of testosterone. 
‘‘(ii) A substance shall not be consid-
ered to be a drug or hormonal substance 
for purposes of this subparagraph if it— 
‘‘(I) is— 
‘‘(aa) an herb or other botan-
ical; 
‘‘(bb) a concentrate, metabo-
lite, or extract of, or a constituent 
isolated directly from, an herb or 
other botanical; or 
‘‘(cc) a combination of 2 or 
more 
substances 
described 
in 
item (aa) or (bb); 
‘‘(II) is a dietary ingredient for 
purposes of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 301 et 
seq.); and 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6202
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
‘‘(III) 
is 
not 
anabolic 
or 
androgenic. 
‘‘(iii) 
In 
accordance 
with 
section 
515(a), any person claiming the benefit of 
an exemption or exception under clause 
(ii) shall bear the burden of going for-
ward with the evidence with respect to 
such exemption or exception.’’. 
(b) CLASSIFICATION
AUTHORITY.—Section 
201 of the Controlled Substances Act (21 
U.S.C. 811) is amended by adding at the end 
the following: 
‘‘(i) TEMPORARY
AND PERMANENT SCHED-
ULING
OF
RECENTLY
EMERGED
ANABOLIC 
STEROIDS.— 
‘‘(1) The Attorney General may issue a 
temporary order adding a drug or other 
substance to the definition of anabolic 
steroids if the Attorney General finds 
that— 
‘‘(A) the drug or other substance 
satisfies the criteria for being consid-
ered an anabolic steroid under sec-
tion 102(41) but is not listed in that 
section or by regulation of the Attor-
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6202
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
ney General as being an anabolic 
steroid; and 
‘‘(B) adding such drug or other 
substance to the definition of ana-
bolic steroids will assist in preventing 
abuse or misuse of the drug or other 
substance. 
‘‘(2) An order issued under paragraph 
(1) shall not take effect until 30 days after 
the date of the publication by the Attor-
ney General of a notice in the Federal 
Register of the intention to issue such 
order and the grounds upon which such 
order is to be issued. The order shall ex-
pire not later than 24 months after the 
date it becomes effective, except that the 
Attorney General may, during the pend-
ency of proceedings under paragraph (6), 
extend the temporary scheduling order 
for up to 6 months. 
‘‘(3) The Attorney General shall trans-
mit notice of an order proposed to be 
issued under paragraph (1) to the Sec-
retary of Health and Human Services. In 
issuing an order under paragraph (1), the 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6202
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
Attorney General shall take into consid-
eration any comments submitted by the 
Secretary in response to a notice trans-
mitted pursuant to this paragraph. 
‘‘(4) A temporary scheduling order 
issued under paragraph (1) shall be va-
cated upon the issuance of a permanent 
scheduling order under paragraph (6). 
‘‘(5) An order issued under paragraph 
(1) is not subject to judicial review. 
‘‘(6) The Attorney General may, by 
rule, issue a permanent order adding a 
drug or other substance to the definition 
of anabolic steroids if such drug or other 
substance satisfies the criteria for being 
considered an anabolic steroid under sec-
tion 102(41). Such rulemaking may be 
commenced 
simultaneously 
with 
the 
issuance of the temporary order issued 
under paragraph (1).’’. 
SEC. 3. LABELING REQUIREMENTS. 
(a) IN GENERAL.—Section 305 of the Con-
trolled Substances Act (21 U.S.C. 825) is 
amended by adding at the end the following: 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6202
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS
‘‘(e) 
FALSE
LABELING
OF
ANABOLIC 
STEROIDS.— 
‘‘(1) It shall be unlawful to import, ex-
port, manufacture, distribute, dispense, 
or possess with intent to manufacture, 
distribute, or dispense, an anabolic ster-
oid or product containing an anabolic 
steroid, unless the steroid or product 
bears a label clearly identifying an ana-
bolic steroid or product containing an an-
abolic steroid by the nomenclature used 
by the International Union of Pure and 
Applied Chemistry (IUPAC). 
‘‘(2)(A) A product described in sub-
paragraph (B) is exempt from the Inter-
national Union of Pure and Applied 
Chemistry nomenclature requirement of 
this subsection if such product is labeled 
in the manner required under the Fed-
eral Food, Drug, and Cosmetic Act. 
‘‘(B) A product is described in this 
subparagraph if the product— 
‘‘(i) is the subject of an approved 
application as described in section 
VerDate Sep 11 2014 
23:04 Sep 15, 2014
Jkt 039200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6202
E:\BILLS\H4771.RH
H4771
tkelley on DSK3SPTVN1PROD with BILLS